

Peter B Bach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10393626/publications.pdf>

Version: 2024-02-01

140
papers

17,500
citations

30551

56
h-index

15253

130
g-index

142
all docs

142
docs citations

142
times ranked

16520
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. Journal of the National Cancer Institute, 2022, 114, 419-426.	3.0	15
2	The Prescription Drug User Fee Act. Medical Care, 2022, Publish Ahead of Print, .	1.1	4
3	Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation. JAMA Network Open, 2022, 5, e223687.	2.8	4
4	Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries. JAMA Network Open, 2021, 4, e210030.	2.8	21
5	Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. Oncologist, 2021, 26, 771-778.	1.9	6
6	Mapping conflict of interests: scoping review. BMJ, The, 2021, 375, e066576.	3.0	14
7	Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014â€“2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, , 1-9.	2.3	5
8	Assessment of variation in 30â€“day mortality following cancer surgeries among older adults across US hospitals. Cancer Medicine, 2020, 9, 1648-1660.	1.3	5
9	Review of Current Policy Strategies to Reduce US Cancer Drug Costs. Journal of Clinical Oncology, 2020, 38, 372-379.	0.8	18
10	Assessing whether cancer stage is needed to evaluate measures of hospital surgical performance. Journal of Evaluation in Clinical Practice, 2020, 26, 66-71.	0.9	2
11	The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating. Pharmacoeconomics, 2020, 38, 737-745.	1.7	5
12	Commentary on Hsiue et al: Cost savings and data limitations of new cancer drug studies. Clinical Trials, 2020, 17, 126-128.	0.7	1
13	Understanding the Rewards of Successful Drug Development â€” Thinking Inside the Box. New England Journal of Medicine, 2020, 382, 473-480.	13.9	12
14	Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care. Journal of the National Cancer Institute, 2020, 112, 1177-1178.	3.0	2
15	Changes in Drug List Prices and Amounts Paid by Patients and Insurers. JAMA Network Open, 2020, 3, e2028510.	2.8	16
16	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. Gynecologic Oncology, 2020, 159, 418-425.	0.6	7
17	Trends in Female Representation on NCCN Guideline Panels. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1084-1086.	2.3	4
18	Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1349-1353.	2.3	0

#	ARTICLE	IF	CITATIONS
19	Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1349-1353.	2.3	9
20	The gender gap in critical care task force participation. <i>Lancet Respiratory Medicine</i> , 2019, 7, 566-567.	5.2	8
21	Preventive Services Offered in Executive Physicals at Top-Ranked Hospitals. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1101.	3.8	7
22	Cancer hospital advertising and outcomes: trust the messenger?. <i>Lancet Oncology</i> , 2019, 20, 760-762.	5.1	3
23	Prescription Drugs' List Price, Net Price, and the Rebate Caught in the Middle. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1563.	3.8	28
24	Female representation among US National Comprehensive Cancer Network guideline panel members. <i>Lancet Oncology</i> , 2019, 20, 327-329.	5.1	9
25	Practice Patterns for Older Adult Patients With Advanced Cancer: Physician Office Versus Hospital Outpatient Setting. <i>Journal of Oncology Practice</i> , 2019, 15, e30-e38.	2.5	4
26	Identifying Cancer-Directed Surgeries in Medicare Claims: A Validation Study Using SEER-Medicare Data. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-24.	1.0	13
27	Which Drug Prices Should Medicare Negotiate? A 'Too Little' or 'Too Late' Approach. <i>New England Journal of Medicine</i> , 2019, 381, 2084-2086.	13.9	4
28	Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion. <i>American Journal of Health Economics</i> , 2019, 5, 360-375.	1.4	2
29	Low-dose CT for lung cancer screening. <i>Lancet Oncology</i> , 2018, 19, e133-e134.	5.1	4
30	Value-Based Pricing for Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2165.	3.8	59
31	Medication overuse in oncology: current trends and future implications for patients and society. <i>Lancet Oncology</i> , 2018, 19, e200-e208.	5.1	33
32	Critical Choices: What Information Do Patients Want When Selecting a Hospital for Cancer Surgery?. <i>Journal of Oncology Practice</i> , 2018, 14, e505-e512.	2.5	11
33	Expansion of the Medicare 340B Payment Program. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2311.	3.8	3
34	Enhancing the Value of the ASCO Value Framework. <i>MDM Policy and Practice</i> , 2018, 3, 238146831877622.	0.5	2
35	National Coverage Analysis of CAR-T Therapies' Policy, Evidence, and Payment. <i>New England Journal of Medicine</i> , 2018, 379, 1396-1398.	13.9	21
36	Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality. <i>JAMA Oncology</i> , 2018, 4, 1006.	3.4	3

#	ARTICLE	IF	CITATIONS
37	Race, Ethnicity, Health Insurance, and Mortality in Older Survivors of Critical Illness. <i>Critical Care Medicine</i> , 2017, 45, e583-e591.	0.4	15
38	Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. <i>JAMA Internal Medicine</i> , 2017, 177, 1185.	2.6	54
39	FDA Approval of Tisagenlecleucel. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1861.	3.8	136
40	Association of Hospital Costs With Complications Following Total Gastrectomy for Gastric Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 953.	2.2	35
41	Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	9
42	Physician's Office and Hospital Outpatient Setting in Oncology: It's About Prices, Not Use. <i>Journal of Oncology Practice</i> , 2017, 13, 4-5.	2.5	4
43	ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy. <i>Journal of Oncology Practice</i> , 2016, 12, 151-152.	2.5	25
44	Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer. <i>JAMA Internal Medicine</i> , 2016, 176, 1541.	2.6	44
45	Overspending driven by oversized single dose vials of cancer drugs. <i>BMJ, The</i> , 2016, 352, i788.	3.0	109
46	Walking the Tightrope Between Treatment Efficacy and Price. <i>Journal of Clinical Oncology</i> , 2016, 34, 889-890.	0.8	10
47	Provider Differences in Use of Implanted Ports in Older Adults With Cancer. <i>Medical Care</i> , 2015, 53, 646-652.	1.1	9
48	Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening. <i>Cancer</i> , 2015, 121, 4341-4347.	2.0	59
49	Pricing in the Market for Anticancer Drugs. <i>Journal of Economic Perspectives</i> , 2015, 29, 139-162.	2.7	379
50	Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits. <i>Oncologist</i> , 2015, 20, 983-984.	1.9	8
51	Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2503.	3.8	66
52	New Math on Drug Cost-Effectiveness. <i>New England Journal of Medicine</i> , 2015, 373, 1797-1799.	13.9	63
53	Complications Associated With Use of Long-Term Central Venous Catheters Among Commercially Insured Women With Breast Cancer. <i>Journal of Oncology Practice</i> , 2015, 11, 505-510.	2.5	4
54	Hospital Volume, Complications, and Cost of Cancer Surgery in the Elderly. <i>Journal of Clinical Oncology</i> , 2015, 33, 107-114.	0.8	97

#	ARTICLE	IF	CITATIONS
55	Bilateral Mastectomy versus Breast-Conserving Surgery for Early-Stage Breast Cancer. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 1518-1526.	0.7	114
56	Wide Variation In Payments For Medicare Beneficiary Oncology Services Suggests Room For Practice-Level Improvement. <i>Health Affairs</i> , 2015, 34, 601-608.	2.5	25
57	Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage. <i>JAMA Oncology</i> , 2015, 1, 1303.	3.4	106
58	Long-Term Central Venous Catheter Use and Risk of Infection in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2351-2356.	0.8	25
59	The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities. <i>Health Affairs</i> , 2014, 33, 1786-1792.	2.5	51
60	Improving Outpatient Oncology Practice: Several Steps Into a Long Journey. <i>Journal of Oncology Practice</i> , 2014, 10, 355-356.	2.5	0
61	Indication-Specific Pricing for Cancer Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1629.	3.8	107
62	Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists. <i>Journal of Clinical Oncology</i> , 2013, 31, 1134-1139.	0.8	113
63	Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. <i>Journal of Oncology Practice</i> , 2013, 9, 54s-59s.	2.5	7
64	Cost Consequences of the 340B Drug Discount Program. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1995.	3.8	48
65	Visions of Hope in Cancer: Focus on Infrastructure. <i>JAMA Internal Medicine</i> , 2013, 173, 979.	2.6	1
66	Perilous potential: The chance to save lives, or lose them, through low dose computed tomography screening for lung cancer. <i>Journal of Surgical Oncology</i> , 2013, 108, 287-288.	0.8	8
67	Changes in the availability of screening mammography, 2000â€“2010. <i>Cancer</i> , 2013, 119, 3847-3853.	2.0	17
68	A Prognostic Model for 6-Month Mortality in Elderly Survivors of Critical Illness. <i>Chest</i> , 2013, 143, 910-919.	0.4	56
69	Lung Cancer Screening: Response. <i>Chest</i> , 2013, 144, 1737-1738.	0.4	0
70	Screening for Lung Cancer. <i>Chest</i> , 2013, 143, e78S-e92S.	0.4	399
71	A Paradigm Shift in U.S. Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2013, 131, 15-23.	0.7	745
72	Infused Chemotherapy Use in the Elderly After Patent Expiration. <i>Journal of Oncology Practice</i> , 2012, 8, e18s-e23s.	2.5	7

#	ARTICLE	IF	CITATIONS
73	The Influence of Sociodemographic Factors and Hospital Characteristics on the Method of Breast Reconstruction, Including Microsurgery. <i>Plastic and Reconstructive Surgery</i> , 2012, 129, 1071-1079.	0.7	110
74	When the Average Applies to No One: Personalized Decision Making About Potential Benefits of Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2012, 157, 571.	2.0	75
75	Benefits and Harms of CT Screening for Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2418.	3.8	1,057
76	Association Between Quality of Care and the Sociodemographic Composition of Physicians' Patient Panels: A Repeat Cross-Sectional Analysis. <i>Journal of General Internal Medicine</i> , 2011, 26, 987-994.	1.3	7
77	Estimating Individual Risk for Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 003-009.	0.8	21
78	Episode-Based Payment For Cancer Care: A Proposed Pilot For Medicare. <i>Health Affairs</i> , 2011, 30, 500-509.	2.5	51
79	Inconsistencies in Findings From the Early Lung Cancer Action Project Studies of Lung Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1002-1006.	3.0	15
80	A Decade of Mortality Reductions in Major Oncologic Surgery. <i>Medical Care</i> , 2010, 48, 1041-1049.	1.1	106
81	Geographic Access and the Use of Screening Mammography. <i>Medical Care</i> , 2010, 48, 349-356.	1.1	87
82	Physician Visits Prior to Treatment for Clinically Localized Prostate Cancer. <i>Archives of Internal Medicine</i> , 2010, 170, 440.	4.3	145
83	Pem and the Cost of Multicycle Maintenance. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1111-1112.	0.5	17
84	A Map to Bad Policy " Hospital Efficiency Measures in the Dartmouth Atlas. <i>New England Journal of Medicine</i> , 2010, 362, 569-574.	13.9	51
85	Commentary: Medicare's 2006 Oncology Demonstration Project: Lost in Translation?. <i>Journal of Oncology Practice</i> , 2010, 6, 59-60.	2.5	1
86	Cancer's Next Frontier. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1086.	3.8	136
87	Primary Care Physicians' Links to Other Physicians Through Medicare Patients: The Scope of Care Coordination. <i>Annals of Internal Medicine</i> , 2009, 150, 236.	2.0	188
88	Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs. <i>New England Journal of Medicine</i> , 2009, 360, 626-633.	13.9	371
89	Smoking as a Factor in Causing Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 539.	3.8	18
90	Is our natural-history model of lung cancer wrong?. <i>Lancet Oncology</i> , The, 2008, 9, 693-697.	5.1	56

#	ARTICLE	IF	CITATIONS
91	Disenrollment From Medicare Managed Care Among Beneficiaries With and Without a Cancer Diagnosis. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1013-1021.	3.0	8
92	Overdiagnosis in lung cancer: different perspectives, definitions, implications. <i>Thorax</i> , 2008, 63, 298-300.	2.7	26
93	Response to "CT Screening for Lung Cancer: Update 2007". <i>Oncologist</i> , 2008, 13, 608-609.	1.9	3
94	Untreated Patients in "CT Screening for Lung Cancer: Update 2007". <i>Oncologist</i> , 2008, 13, 1030-1032.	1.9	5
95	Do Surgical Quality Gaps Cause Healthcare Disparities?. <i>Medical Care</i> , 2008, 46, 889-892.	1.1	4
96	Lung Cancer Screening. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 271-275.	2.3	9
97	Costs of Cancer Care: A View From the Centers for Medicare & Medicaid Services. <i>Journal of Clinical Oncology</i> , 2007, 25, 187-190.	0.8	35
98	Screening for Lung Cancer. <i>Chest</i> , 2007, 132, 69S-77S.	0.4	139
99	Care Patterns in Medicare and Their Implications for Pay for Performance. <i>New England Journal of Medicine</i> , 2007, 356, 1130-1139.	13.9	450
100	Computed Tomography Screening and Lung Cancer Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 953.	3.8	490
101	Potentially Avoidable Hospitalizations for COPD and Pneumonia. <i>Medical Care</i> , 2007, 45, 562-570.	1.1	45
102	Fragmentation of Care for Frequently Hospitalized Urban Residents. <i>Medical Care</i> , 2006, 44, 560-567.	1.1	63
103	The First Months of the Prescription-Drug Benefit " A CMS Update. <i>New England Journal of Medicine</i> , 2006, 354, 2312-2314.	13.9	34
104	Validation of a Model of Lung Cancer Risk Prediction Among Smokers. <i>Journal of the National Cancer Institute</i> , 2006, 98, 637-640.	3.0	66
105	The Association between Hospital Volume and Total Shoulder Arthroplasty Outcomes. <i>Clinical Orthopaedics and Related Research</i> , 2005, 432, 132-137.	0.7	77
106	Using Practice Guidelines to Assess Cancer Care Quality. <i>Journal of Clinical Oncology</i> , 2005, 23, 9041-9043.	0.8	22
107	A Prescription for a Modern Medicare Program. <i>New England Journal of Medicine</i> , 2005, 353, 2733-2735.	13.9	26
108	Delivery of Preventive Services to Older Adults by Primary Care Physicians. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 473.	3.8	243

#	ARTICLE	IF	CITATIONS
109	Primary Care Physicians Who Treat Blacks and Whites. <i>New England Journal of Medicine</i> , 2004, 351, 575-584.	13.9	865
110	Lung Cancer in US Women. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1763.	3.8	220
111	Resurrecting Treatment Histories of Dead Patients. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2765.	3.8	220
112	Benchmarking Lung Cancer Mortality Rates in Current and Former Smokers. <i>Chest</i> , 2004, 126, 1742-1749.	0.4	44
113	Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. <i>Journal of Surgical Oncology</i> , 2003, 83, 68-78.	0.8	202
114	Perspectives on the Value of American Society of Clinical Oncology Clinical Guidelines as Reported by Oncologists and Health Maintenance Organizations. <i>Journal of Clinical Oncology</i> , 2003, 21, 937-941.	0.8	36
115	Variations in Lung Cancer Risk Among Smokers. <i>Journal of the National Cancer Institute</i> , 2003, 95, 470-478.	3.0	547
116	Adherence to Surveillance Among Patients With Superficial Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 588-597.	3.0	127
117	Screening for Lung Cancer*. <i>Chest</i> , 2003, 123, 72S-82S.	0.4	242
118	Screening for Lung Cancer*. <i>Chest</i> , 2003, 123, 83S-88S.	0.4	86
119	The Effect of Clustering of Outcomes on the Association of Procedure Volume and Surgical Outcomes. <i>Annals of Internal Medicine</i> , 2003, 139, 658.	2.0	280
120	Consider saying yes *. <i>Critical Care Medicine</i> , 2003, 31, 320-321.	0.4	19
121	Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3999-4005.	0.8	226
122	State Expenditures for Tobacco-Control Programs and the Tobacco Settlement. <i>New England Journal of Medicine</i> , 2002, 347, 1080-1086.	13.9	66
123	Variations in Morbidity after Radical Prostatectomy. <i>New England Journal of Medicine</i> , 2002, 346, 1138-1144.	13.9	800
124	Identifying and Measuring Hospital Characteristics Using the SEER-Medicare Data and Other Claims-Based Sources. <i>Medical Care</i> , 2002, 40, IV-96-IV-103.	1.1	51
125	Overview of the SEER-Medicare Data. <i>Medical Care</i> , 2002, 40, IV-3-IV-18.	1.1	712
126	Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database. <i>Medical Care</i> , 2002, 40, IV-19-IV-25.	1.1	200

#	ARTICLE	IF	CITATIONS
127	Hospital and Surgeon Procedure Volume as Predictors of Outcome Following Rectal Cancer Resection. <i>Annals of Surgery</i> , 2002, 236, 583-592.	2.1	306
128	Survival of Blacks and Whites After a Cancer Diagnosis. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 2106.	3.8	444
129	The epidemiology and costs of chronic critical illness. <i>Critical Care Clinics</i> , 2002, 18, 461-476.	1.0	197
130	Impact of Infection by Vancomycin-Resistant Enterococcus on Survival and Resource Utilization for Patients With Leukemia. <i>Infection Control and Hospital Epidemiology</i> , 2002, 23, 471-474.	1.0	18
131	Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. <i>Medical Care</i> , 2002, 40, IV-3-18.	1.1	1,089
132	Who Gets Adjuvant Treatment for Stage II and III Rectal Cancer? Insight From Surveillance, Epidemiology, and End Resultsâ€“Medicare. <i>Journal of Clinical Oncology</i> , 2001, 19, 3712-3718.	0.8	147
133	Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. <i>Blood</i> , 2001, 98, 3234-3240.	0.6	106
134	Predicting Mortality in Patients Suffering From Prolonged Critical Illness. <i>Chest</i> , 2001, 120, 928-933.	0.4	62
135	Age and Adjuvant Chemotherapy Use After Surgery for Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2001, 93, 850-857.	3.0	450
136	Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Summary and Appraisal of Published Evidence. <i>Annals of Internal Medicine</i> , 2001, 134, 600.	2.0	230
137	The Influence of Hospital Volume on Survival after Resection for Lung Cancer. <i>New England Journal of Medicine</i> , 2001, 345, 181-188.	13.9	656
138	Identifying Providers of Care to Individuals with Human Immunodeficiency Virus for a Mail Survey Using a Prescription Tracking Database. <i>Journal of Clinical Epidemiology</i> , 1999, 52, 147-150.	2.4	2
139	Racial Differences in the Treatment of Early-Stage Lung Cancer. <i>New England Journal of Medicine</i> , 1999, 341, 1198-1205.	13.9	944
140	The Relation Between Physician Experience and Patterns of Care for Patients With AIDS-Related <i>Pneumocystis carinii</i> Pneumonia. <i>Chest</i> , 1999, 115, 1563-1569.	0.4	9